394 related articles for article (PubMed ID: 10481945)
1. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma.
Simpson JF; O'Malley F; Dupont WD; Page DL
Cancer; 1994 May; 73(9):2352-8. PubMed ID: 7513249
[TBL] [Abstract][Full Text] [Related]
4. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
5. Ductal carcinoma in situ of the breast: histological classification and genetic alterations.
van de Vijver MJ
Recent Results Cancer Res; 1998; 152():123-34. PubMed ID: 9928552
[TBL] [Abstract][Full Text] [Related]
6. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.
Done SJ; Eskandarian S; Bull S; Redston M; Andrulis IL
J Natl Cancer Inst; 2001 May; 93(9):700-4. PubMed ID: 11333292
[TBL] [Abstract][Full Text] [Related]
7. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of gelsolin correlates with the progression to breast carcinoma.
Winston JS; Asch HL; Zhang PJ; Edge SB; Hyland A; Asch BB
Breast Cancer Res Treat; 2001 Jan; 65(1):11-21. PubMed ID: 11245335
[TBL] [Abstract][Full Text] [Related]
9. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
10. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
Seth A; Kitching R; Landberg G; Xu J; Zubovits J; Burger AM
Anticancer Res; 2003; 23(3A):2043-51. PubMed ID: 12894577
[TBL] [Abstract][Full Text] [Related]
12. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
13. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade.
Sowter HM; Ferguson M; Pym C; Watson P; Fox SB; Han C; Harris AL
J Pathol; 2003 Dec; 201(4):573-80. PubMed ID: 14648660
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
15. Minimal breast cancer: evaluation of histology and biological marker expression.
Dublin EA; Millis RR; Smith P; Bobrow LG
Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
17. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
19. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of ductal carcinoma in-situ of breast and its correlation with the grade of associated invasive component.
Konar K; Chatterjee U; Dutta SK
Indian J Pathol Microbiol; 2001 Jul; 44(3):297-300. PubMed ID: 12024916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
